Inifatamab Deruxtecan: Lung Cancer Treatment Results
Here’s a summary of the key findings from the provided text:
Target & Context: 7-H3 is overexpressed in all subtypes of Small Cell Lung Cancer (SCLC) adn linked to poorer outcomes, making it a promising therapeutic target. This study focuses on ifinatamab deruxtecan (I-DXd) as a potential treatment.
Study Details: The analysis included 137 patients wiht SCLC treated with I-DXd (12mg/kg IV every three weeks). Patients had received 1-3 prior lines of systemic therapy.
Efficacy:
Response Rate (ORR): Meaningful response rates were observed.
Duration of Response: 5.3 months
Time to Response: 1.4 months
Progression-Free Survival (PFS): 4.9 months
Overall Survival (OS): 10.3 months
Benefit Across Subgroups: clinical benefit was seen regardless of platinum sensitivity or prior treatment history. Second-line patients (n=32) showed numerically longer PFS and OS than the overall population, with an ORR of 56.3%.
safety:
TRAEs: 89.8% of patients experienced treatment-related adverse events (TRAEs).
Grade 3+ TRAEs: 36.5% of patients experienced grade 3 or higher TRAEs.
Grade 5 TRAEs: 4.4% of patients experienced grade 5 (fatal) TRAEs.
Interstitial Lung Disease/Pneumonitis: Occurred in 17 patients (6 were grade ≥3).
Overall: Safety findings were consistent with previous reports, with no new safety concerns identified.
Conclusion: Dr. Ahn highlights the “remarkable efficacy” of I-DXd in this patient population with significant unmet needs and supports further examination of the drug for SCLC.